FR2710243A1 - High-energy composition based on branched-chain amino acids - Google Patents
High-energy composition based on branched-chain amino acids Download PDFInfo
- Publication number
- FR2710243A1 FR2710243A1 FR9408545A FR9408545A FR2710243A1 FR 2710243 A1 FR2710243 A1 FR 2710243A1 FR 9408545 A FR9408545 A FR 9408545A FR 9408545 A FR9408545 A FR 9408545A FR 2710243 A1 FR2710243 A1 FR 2710243A1
- Authority
- FR
- France
- Prior art keywords
- composition
- amino acids
- energy
- branched
- chain amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
COMPOSITION ENERGETIQUE
A BASE D'ACIDES AMINES A CHAINE RAMIFIEE
La présente Invention se rapporte à une composition énergétique destinée à être utilisée en complément de l'alimentation et propre à améliorer la balance azotée chez des sujets ayant une activité musculaire intense tels que les sportifs.ENERGY COMPOSITION
BASED ON BRANCHED CHAIN AMINO ACIDS
The present invention relates to an energy composition intended to be used in addition to food and suitable for improving the nitrogen balance in subjects with intense muscular activity such as sportsmen.
Au cours d'une activité musculaire intense, les muscles servent à convertir l'énergie chimique en travail mécanique. L'ATP est la source d'énergie chimique cellulaire ; il est produit généralement par l'oxydation des substances nutritives (glucides, protides, lipides) dans le muscle lui-même. During intense muscular activity, muscles are used to convert chemical energy into mechanical work. ATP is the source of cellular chemical energy; it is generally produced by the oxidation of nutrients (carbohydrates, proteins, lipids) in the muscle itself.
Toutefois, l'ATP n a pas comme fonction principale un rôle de réservoir d'énergie chimique ; il agit surtout comme un transmetteur ou un transporteur d'énergie. Aussi, la quantité d' ATP présente dans les cellules musculaires, à un moment donné, ne permet de couvrir qu'un besoin de courte durée. However, ATP does not have as main function a reservoir of chemical energy; it acts mainly as a transmitter or transporter of energy. Also, the amount of ATP present in muscle cells, at a given time, only covers a short-term need.
I1 s'ensuit que l'organisme est obligé de puiser dans ses réserves énergétiques, c'est à dire - les carburants circulants représentés par 20 g de glucose, 300 mg d'acides gras, quelques mg de triglycérides et quelques microgrammes d'acides aminés, soit moins de 100 kilocalories - le glycogène musculaire et hépatique dont la dégradation en glucose est génératrice d'ATP - les lipides qui, stockés dans le tissu adipeux essentiellement sous forme de triglycérides, sont libérés sous forme de glycérol et d'acides gras libres mais également, - le stock protéique, sous forme surtout de protéines musculaires, dont le catabolisme peut conduire à la production d'énergie mais avec un mauvais rendement et au détriment des synthèses protéiques. It follows that the body is forced to draw on its energy reserves, that is to say - the circulating fuels represented by 20 g of glucose, 300 mg of fatty acids, a few mg of triglycerides and a few micrograms of acids. amino acids, less than 100 kilocalories - muscle and liver glycogen, the breakdown of which in glucose generates ATP - lipids which, stored in fatty tissue mainly in the form of triglycerides, are released in the form of glycerol and fatty acids free but also, - the protein stock, mainly in the form of muscle proteins, the catabolism of which can lead to energy production but with poor performance and to the detriment of protein synthesis.
L'Inventeur s'est, en conséquence, fixé pour but de pourvoir à une composition énergétique dont l'administration par voie orale, en complément de l'alimentation habituelle, permet de suppléer aux besoins énergétiques des muscles et d'éviter que ceux-ci ne puisent dans leurs réserves, notamment en protéines. The inventor therefore set himself the goal of providing an energy composition whose administration by oral route, in addition to the usual diet, makes it possible to supply the energy needs of the muscles and to prevent them from being they do not draw on their reserves, especially in proteins.
La présente Invention a, donc, pour objet une composition énergétique caractérisée en ce quelle présente la formulation suivante, exprimée en pourcentages du poids total de la composition - L-valine ................................. 22,5 à 27,5% - L-leucine ................................ 40 à 45% - L-isoleucine ............................. 15,5 à 19,5% - L-ornithine ................................. 8,5 à 12% - Pyridoxine ................................. 0,7 à 1,7% - Dextrine . ................ ....... ............ 2 à 4%
Dans une forme de réalisation préférée, la composition présente la formulation suivante, exprimée en pourcentages du poids total de la composition - L-valine ...................................... 24,797% - L-leucine ..................................... 42,683% - L-isoleucine ................................... 17,48% - L-ornithine ................................... 10,773% - Pyridoxine ...................................... 1,22% - Dextrine ...................................... 3,0487%
Avantageusement, la composition est administrable par voie orale sous forme de comprimés ou de gélules.The present invention therefore relates to an energy composition characterized in that it has the following formulation, expressed as percentages of the total weight of the composition - L-valine ................ ................. 22.5 to 27.5% - L-leucine ..................... ........... 40 to 45% - L-isoleucine ............................. 15, 5 to 19.5% - L-ornithine ................................. 8.5 to 12% - Pyridoxine ................................. 0.7 to 1.7% - Dextrin. ................ ....... ............ 2 to 4%
In a preferred embodiment, the composition has the following formulation, expressed as percentages of the total weight of the composition - L-valine ....................... ............... 24.797% - L-leucine ............................. ........ 42.683% - L-isoleucine ................................... 17 , 48% - L-ornithine ................................... 10,773% - Pyridoxine .... .................................. 1.22% - Dextrin .......... ............................ 3.0487%
Advantageously, the composition can be administered orally in the form of tablets or capsules.
De façon particulièrement avantageuse, pour la préparation de comprimés ou de gélules, la composition est mélangée à un excipient convenable choisi parmi le stéarate de magnésium et/ou le lactose. In a particularly advantageous way, for the preparation of tablets or capsules, the composition is mixed with a suitable excipient chosen from magnesium stearate and / or lactose.
En effet, l'inventeur a découvert qu'en associant dans une composition, dans des proportions appropriées - les acides aminés à chaîne ramifiée, à savoir la leucine, l'isoleucine et la valine, de préférence sous leur forme lévogyre directement utilisable par les cellules, qui favorisent la synthèse protéique et freinent la protéolyse musculaire, - l'ornithine qui représente un produit intermédiaire du cycle de l'urée et favorise à ce titre le déroulement de ce cycle tout en stimulant la synthèse protéique, - la pyridoxine ou vitamine B6 qui joue un rôle de coenzyme dans de nombreuses réactions métaboliques des acides aminés ainsi qu'un rôle de vecteur des métabolites obtenus, - ainsi qu'à une dextrine, polyoside à haute teneur énergétique, on obtient un effet synergique positif de ces constituants sur le métabolisme et la synthèse protéique se traduisant par une amélioration de la balance azotée. Indeed, the inventor has discovered that by combining in a composition, in appropriate proportions - the branched chain amino acids, namely leucine, isoleucine and valine, preferably in their levorotatory form directly usable by cells, which promote protein synthesis and slow down muscle proteolysis, - ornithine which represents an intermediate product of the urea cycle and as such promotes the progress of this cycle while stimulating protein synthesis, - pyridoxine or vitamin B6 which plays a coenzyme role in many metabolic reactions of amino acids as well as a vector role of the metabolites obtained, - as well as a dextrin, polysaccharide with high energy content, we obtain a positive synergistic effect of these constituents on metabolism and protein synthesis resulting in an improvement of the nitrogen balance.
EXEMPLE DE RELLISATION D'UNE COMPOSITION CONFORME A
L'INVENTION :
Une composition conforme à l'invention est préparée en mélangeant les différents constituants, de sorte à obtenir par comprimé - L-valine ........................ 122 mg (soit 24,797%) - L-leucine ....................... 210 mg (soit 42,683%) - L-isoleucine ...................... 86 mg (soit 17,48%) - L-ornithine ...................... 53 mg (soit 10,773%) - Pyridoxine .......................... 6 mg (soit 1,22%) - Dextrine ......................... 15 mg (soit 3,0487%)
Après addition de l'excipient, le mélange est comprimé à froid pour garantir la stabilité chimique et physique de la composition.EXAMPLE OF RELLIZATION OF A COMPOSITION CONFORMING TO
THE INVENTION:
A composition in accordance with the invention is prepared by mixing the various constituents, so as to obtain per tablet - L-valine ........................ 122 mg (i.e. 24.797%) - L-leucine ....................... 210 mg (i.e. 42.683%) - L-isoleucine ...... ................ 86 mg (i.e. 17.48%) - L-ornithine ..................... 53 mg (i.e. 10.773%) - Pyridoxine .......................... 6 mg (i.e. 1.22%) - Dextrin ... ...................... 15 mg (i.e. 3.0487%)
After addition of the excipient, the mixture is cold compressed to guarantee the chemical and physical stability of the composition.
Les acides aminés utilisables pour la mise en oeuvre de la présente Invention peuvent avantageusement être obtenus par un procédé d'hydrolyse des protéines extraites de graines de soja, mais aussi par les procédés classiques de synthèse des acides aminés de l'Art
Antérieur.The amino acids which can be used for the implementation of the present invention can advantageously be obtained by a process for the hydrolysis of proteins extracted from soybeans, but also by the conventional processes for the synthesis of amino acids in the art.
Prior.
Des études cliniques ont montré que la prise quotidienne d'une quantité suffisante (environ 1,5 g) d'une composition énergétique conforme à l'invention, en complément de l'alimentation habituelle, permet d'améliorer la performance et la tolérance du muscle à l'effort. Clinical studies have shown that the daily intake of a sufficient quantity (approximately 1.5 g) of an energy composition in accordance with the invention, in addition to the usual diet, makes it possible to improve the performance and the tolerance of the muscle on exertion.
Ainsi que cela ressort de ce qui précède, l'invention ne se limite nullement au mode de réalisation qui vient d'être décrit de façon plus explicite ; elle en embrasse au contraire toutes les variantes qui peuvent venir à l'esprit du technicien en la matière, sans s'écarter du cadre, ni de la portée de la présente
Invention. As is apparent from the above, the invention is in no way limited to the embodiment which has just been described more explicitly; on the contrary, it embraces all variants which may come to the mind of the technician in the matter, without departing from the framework or the scope of this
Invention.
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU88369A LU88369A1 (en) | 1993-07-12 | 1993-07-12 | Branched chain amino acids |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2710243A1 true FR2710243A1 (en) | 1995-03-31 |
FR2710243B3 FR2710243B3 (en) | 1995-10-13 |
Family
ID=19731415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9408545A Expired - Fee Related FR2710243B3 (en) | 1993-07-12 | 1994-07-11 | Energy composition based on branched chain amino acids. |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2710243B3 (en) |
LU (1) | LU88369A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002102360A2 (en) * | 2001-06-15 | 2002-12-27 | Professional Dietetics S.R.L. | Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes |
WO2013134736A1 (en) * | 2012-03-08 | 2013-09-12 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9072692B2 (en) | 2011-07-15 | 2015-07-07 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9707213B2 (en) | 2013-03-15 | 2017-07-18 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
US9724319B2 (en) | 2014-02-27 | 2017-08-08 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US9943517B2 (en) | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
-
1993
- 1993-07-12 LU LU88369A patent/LU88369A1/en unknown
-
1994
- 1994-07-11 FR FR9408545A patent/FR2710243B3/en not_active Expired - Fee Related
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002102360A3 (en) * | 2001-06-15 | 2003-05-30 | Professional Dietetics Srl | Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes |
WO2002102360A2 (en) * | 2001-06-15 | 2002-12-27 | Professional Dietetics S.R.L. | Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes |
US9682053B2 (en) | 2011-07-15 | 2017-06-20 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US10076507B1 (en) | 2011-07-15 | 2018-09-18 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9072692B2 (en) | 2011-07-15 | 2015-07-07 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9855235B2 (en) | 2011-07-15 | 2018-01-02 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9351967B2 (en) | 2011-07-15 | 2016-05-31 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
US9408410B2 (en) | 2012-03-08 | 2016-08-09 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9901573B2 (en) | 2012-03-08 | 2018-02-27 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9713609B2 (en) | 2012-03-08 | 2017-07-25 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
WO2013134736A1 (en) * | 2012-03-08 | 2013-09-12 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US10646489B2 (en) | 2012-11-13 | 2020-05-12 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
US9943517B2 (en) | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
US9707213B2 (en) | 2013-03-15 | 2017-07-18 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
US9895357B2 (en) | 2013-03-15 | 2018-02-20 | Nusirt Sciences, Inc. | Compositions, methods and kits for reducing lipid levels |
US9872844B2 (en) | 2014-02-27 | 2018-01-23 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US9724319B2 (en) | 2014-02-27 | 2017-08-08 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
Also Published As
Publication number | Publication date |
---|---|
LU88369A1 (en) | 1994-04-01 |
FR2710243B3 (en) | 1995-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4528925B2 (en) | Amino acid composition and fluid replacement | |
US5863906A (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
EP1515712A2 (en) | Use of taurine for the treatment of alopecia | |
FR2710243A1 (en) | High-energy composition based on branched-chain amino acids | |
EP0655244B1 (en) | Amino acid composition for the treatment of infections | |
EP1296675B1 (en) | Compositions based on aminoacids, suitable for the treatment of heart failure | |
FR2825004A1 (en) | SATIANT DIETETIC PRODUCT | |
EP0280593B1 (en) | Composition on the basis of an amino-acid and vitamins for use in cancer therapy | |
JP4009682B2 (en) | Adrenaline and noradrenaline secretion promoting composition | |
EP1296668A2 (en) | Compositions based on aminoacids, suitable for improving muscle performance | |
US20080161380A1 (en) | Amino acid composition | |
BE1026496B1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder | |
EP0108017B1 (en) | Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles | |
FR2710242A1 (en) | High-energy composition based on amino acids | |
FR2880538A1 (en) | Composition, useful in an anti-inflammatory and moisturizing for skin, comprises fish oil and phospholipids | |
WO2016062830A1 (en) | Composition comprising plant proteins and use for preventing metabolic and cardiovascular pathological conditions associated with cardiometabolic risk in particular with hyperglycaemia | |
EP0086680B1 (en) | Strong anti-asthenic compositions containing a double salt of ascorbic acid and amino-diacids | |
FR2710241A1 (en) | High-energy composition based on glycogenic amino acids | |
FR2643266A1 (en) | Solution supplying amino acids for parenteral nutrition | |
EP3738596B1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder | |
CN115245201A (en) | Nutritional composition for improving sarcopenia and application thereof | |
JP4147280B2 (en) | Glutamine-containing energy-added amino acid composition or amino acid solution | |
EP0295166A1 (en) | Pharmaceutical compositions containing a mixture of salts of keto-acids and amino-acids | |
WO2020229443A1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder | |
EP0452210A1 (en) | Pharmaceutical and/or dietetic compositions containing carnitine, lysine and methionine with or without pantothenic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |